Amygdala
Amygdala acquires Gilead’s candidate for addiction treatment
February 20, 2017Manufacturing and Production, Sales and Marketing Amygdala, Gilead
Amygdala Neurosciences, a biopharmaceutical company that develops and commercialises drugs for the treatment of addiction disorders, has agreed an acquisition …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
